 Omar Khan
Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bariatric Surgery | 7 | 2023 | 217 | 3.030 |
Why?
| | Obesity, Morbid | 6 | 2023 | 264 | 1.420 |
Why?
| | Gastrectomy | 5 | 2023 | 126 | 0.890 |
Why?
| | Global Health | 2 | 2016 | 386 | 0.720 |
Why?
| | Gastric Bypass | 4 | 2023 | 119 | 0.590 |
Why?
| | Health Care Costs | 1 | 2020 | 398 | 0.540 |
Why?
| | Prejudice | 1 | 2017 | 73 | 0.530 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 293 | 0.520 |
Why?
| | International Educational Exchange | 1 | 2016 | 12 | 0.500 |
Why?
| | Carcinoma, Renal Cell | 3 | 2023 | 217 | 0.490 |
Why?
| | Fractures, Bone | 1 | 2020 | 380 | 0.470 |
Why?
| | Physicians, Primary Care | 1 | 2017 | 236 | 0.450 |
Why?
| | Attitude to Health | 1 | 2017 | 439 | 0.430 |
Why?
| | Kidney Neoplasms | 3 | 2023 | 403 | 0.420 |
Why?
| | Education, Medical, Undergraduate | 1 | 2016 | 188 | 0.420 |
Why?
| | Maternal Death | 1 | 2013 | 11 | 0.410 |
Why?
| | Obesity | 4 | 2023 | 2992 | 0.400 |
Why?
| | Maternal Health Services | 1 | 2013 | 98 | 0.370 |
Why?
| | Schools, Medical | 1 | 2013 | 147 | 0.370 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1291 | 0.360 |
Why?
| | Quality Assurance, Health Care | 1 | 2013 | 322 | 0.350 |
Why?
| | Registries | 5 | 2023 | 2035 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2531 | 0.320 |
Why?
| | Insulin | 1 | 2020 | 2409 | 0.320 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1171 | 0.320 |
Why?
| | Kidney Transplantation | 1 | 2016 | 708 | 0.310 |
Why?
| | Weight Loss | 4 | 2023 | 787 | 0.310 |
Why?
| | Endpoint Determination | 1 | 2009 | 77 | 0.300 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1050 | 0.300 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 132 | 0.290 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2009 | 76 | 0.290 |
Why?
| | Health Promotion | 1 | 2013 | 741 | 0.260 |
Why?
| | United Kingdom | 4 | 2023 | 318 | 0.260 |
Why?
| | Pelizaeus-Merzbacher Disease | 1 | 2006 | 3 | 0.250 |
Why?
| | RNA, Small Interfering | 4 | 2019 | 622 | 0.250 |
Why?
| | Neuromyelitis Optica | 2 | 2017 | 132 | 0.220 |
Why?
| | Endothelium, Vascular | 2 | 2021 | 927 | 0.210 |
Why?
| | Humans | 28 | 2023 | 137585 | 0.200 |
Why?
| | Gastrointestinal Hormones | 1 | 2021 | 5 | 0.180 |
Why?
| | Iron-Binding Proteins | 1 | 2021 | 44 | 0.180 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 113 | 0.170 |
Why?
| | Models, Economic | 1 | 2020 | 58 | 0.170 |
Why?
| | Cost Savings | 1 | 2020 | 84 | 0.170 |
Why?
| | Multiple Sclerosis | 3 | 2010 | 455 | 0.170 |
Why?
| | Postprandial Period | 1 | 2021 | 107 | 0.170 |
Why?
| | Friedreich Ataxia | 1 | 2021 | 75 | 0.160 |
Why?
| | Drug Costs | 1 | 2020 | 106 | 0.160 |
Why?
| | Bile Acids and Salts | 1 | 2021 | 200 | 0.160 |
Why?
| | Cellular Senescence | 1 | 2021 | 189 | 0.160 |
Why?
| | Vascular Remodeling | 1 | 2021 | 193 | 0.150 |
Why?
| | Hypertension, Pulmonary | 2 | 2021 | 1910 | 0.150 |
Why?
| | Gastroplasty | 1 | 2018 | 30 | 0.150 |
Why?
| | Glycine | 1 | 2019 | 176 | 0.140 |
Why?
| | Bayes Theorem | 1 | 2020 | 405 | 0.140 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 591 | 0.140 |
Why?
| | England | 1 | 2017 | 97 | 0.140 |
Why?
| | Treatment Failure | 1 | 2018 | 356 | 0.130 |
Why?
| | Adult | 9 | 2023 | 37929 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2023 | 10811 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 257 | 0.130 |
Why?
| | Diabetes Complications | 1 | 2018 | 227 | 0.130 |
Why?
| | Middle Aged | 6 | 2023 | 33479 | 0.130 |
Why?
| | Female | 12 | 2023 | 73304 | 0.120 |
Why?
| | Gastroesophageal Reflux | 1 | 2018 | 234 | 0.120 |
Why?
| | Capacity Building | 1 | 2016 | 63 | 0.120 |
Why?
| | Reoperation | 1 | 2018 | 573 | 0.120 |
Why?
| | Cultural Competency | 1 | 2016 | 85 | 0.120 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2015 | 40 | 0.120 |
Why?
| | Databases, Factual | 1 | 2020 | 1357 | 0.110 |
Why?
| | Dextrans | 1 | 2015 | 84 | 0.110 |
Why?
| | Weight Gain | 1 | 2018 | 519 | 0.110 |
Why?
| | Male | 10 | 2023 | 67762 | 0.110 |
Why?
| | Brain | 1 | 2006 | 2668 | 0.110 |
Why?
| | Developing Countries | 1 | 2016 | 307 | 0.110 |
Why?
| | Gene Silencing | 1 | 2014 | 195 | 0.100 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 810 | 0.100 |
Why?
| | Antibodies | 1 | 2015 | 410 | 0.100 |
Why?
| | Nanostructures | 1 | 2014 | 107 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2016 | 397 | 0.100 |
Why?
| | Patient Readmission | 1 | 2018 | 697 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1215 | 0.100 |
Why?
| | Pilot Projects | 1 | 2017 | 1710 | 0.090 |
Why?
| | International Cooperation | 1 | 2013 | 198 | 0.090 |
Why?
| | Gene Expression | 2 | 2014 | 1502 | 0.090 |
Why?
| | Cohort Studies | 2 | 2021 | 5742 | 0.090 |
Why?
| | Graft Rejection | 1 | 2016 | 624 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2017 | 786 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 365 | 0.090 |
Why?
| | Program Evaluation | 1 | 2016 | 898 | 0.090 |
Why?
| | Transfection | 1 | 2014 | 945 | 0.090 |
Why?
| | Social Environment | 1 | 2013 | 296 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 466 | 0.090 |
Why?
| | Myocardium | 1 | 2016 | 1002 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2010 | 236 | 0.080 |
Why?
| | Age Factors | 1 | 2017 | 3295 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 6828 | 0.080 |
Why?
| | Education, Medical | 1 | 2013 | 266 | 0.080 |
Why?
| | Major Histocompatibility Complex | 1 | 2010 | 227 | 0.080 |
Why?
| | Lipids | 1 | 2014 | 672 | 0.080 |
Why?
| | Neuroprotective Agents | 1 | 2010 | 131 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 203 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1692 | 0.080 |
Why?
| | Hypertension | 1 | 2018 | 1295 | 0.080 |
Why?
| | Sample Size | 1 | 2009 | 125 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1313 | 0.070 |
Why?
| | Quality of Life | 1 | 2020 | 2892 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2016 | 2475 | 0.070 |
Why?
| | Research Design | 1 | 2015 | 1139 | 0.070 |
Why?
| | Macrophages | 1 | 2016 | 1547 | 0.070 |
Why?
| | Stroke | 1 | 2017 | 1120 | 0.070 |
Why?
| | Secondary Prevention | 1 | 2009 | 233 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 692 | 0.070 |
Why?
| | Genome, Human | 1 | 2010 | 425 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 363 | 0.070 |
Why?
| | United States | 2 | 2016 | 14841 | 0.070 |
Why?
| | Primary Health Care | 1 | 2017 | 1738 | 0.070 |
Why?
| | Retrospective Studies | 2 | 2023 | 15657 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 804 | 0.060 |
Why?
| | Fabry Disease | 1 | 2006 | 2 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2018 | 2654 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5472 | 0.060 |
Why?
| | Curriculum | 1 | 2013 | 992 | 0.060 |
Why?
| | Prospective Studies | 1 | 2018 | 7604 | 0.060 |
Why?
| | Demyelinating Diseases | 1 | 2006 | 85 | 0.060 |
Why?
| | Mice | 6 | 2021 | 17787 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2019 | 5757 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 660 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2019 | 4193 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2057 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3284 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2010 | 2426 | 0.060 |
Why?
| | Myelin Sheath | 1 | 2006 | 167 | 0.050 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2526 | 0.050 |
Why?
| | State Medicine | 1 | 2023 | 24 | 0.050 |
Why?
| | Heart Failure | 1 | 2016 | 2236 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2833 | 0.050 |
Why?
| | Aged | 2 | 2022 | 23961 | 0.050 |
Why?
| | Bevacizumab | 1 | 2022 | 138 | 0.040 |
Why?
| | Endothelial Progenitor Cells | 1 | 2021 | 20 | 0.040 |
Why?
| | Chenodeoxycholic Acid | 1 | 2021 | 16 | 0.040 |
Why?
| | Ursodeoxycholic Acid | 1 | 2021 | 21 | 0.040 |
Why?
| | Secretory Pathway | 1 | 2021 | 8 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3015 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 217 | 0.040 |
Why?
| | Animals | 6 | 2021 | 36940 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2021 | 199 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2016 | 2167 | 0.040 |
Why?
| | Cell Respiration | 1 | 2019 | 103 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 545 | 0.040 |
Why?
| | Iron-Sulfur Proteins | 1 | 2019 | 46 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 564 | 0.040 |
Why?
| | Haplotypes | 2 | 2010 | 494 | 0.040 |
Why?
| | Administration, Oral | 1 | 2021 | 816 | 0.040 |
Why?
| | Eating | 1 | 2021 | 380 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2022 | 1993 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2016 | 88 | 0.030 |
Why?
| | Mutation | 2 | 2019 | 3958 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2757 | 0.030 |
Why?
| | RNAi Therapeutics | 1 | 2015 | 6 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1060 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2014 | 82 | 0.030 |
Why?
| | Triazines | 1 | 2014 | 43 | 0.030 |
Why?
| | HIV | 1 | 2015 | 234 | 0.030 |
Why?
| | ras Proteins | 1 | 2014 | 153 | 0.030 |
Why?
| | Nanotechnology | 1 | 2014 | 125 | 0.030 |
Why?
| | Young Adult | 2 | 2021 | 13209 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 267 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1483 | 0.020 |
Why?
| | Cisplatin | 1 | 2014 | 320 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 320 | 0.020 |
Why?
| | HeLa Cells | 1 | 2014 | 636 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2015 | 483 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1236 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 648 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2010 | 18 | 0.020 |
Why?
| | Allelic Imbalance | 1 | 2010 | 9 | 0.020 |
Why?
| | INDEL Mutation | 1 | 2010 | 16 | 0.020 |
Why?
| | Calcineurin Inhibitors | 1 | 2010 | 72 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2014 | 528 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1793 | 0.020 |
Why?
| | Interferon-beta | 1 | 2010 | 92 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 157 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 112 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 268 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 847 | 0.020 |
Why?
| | Breast | 1 | 2010 | 151 | 0.020 |
Why?
| | Heterozygote | 1 | 2010 | 293 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 228 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 182 | 0.020 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 226 | 0.020 |
Why?
| | Genetics, Population | 1 | 2010 | 214 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4295 | 0.020 |
Why?
| | Nanoparticles | 1 | 2014 | 481 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2010 | 380 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5131 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2014 | 940 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 891 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 660 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3412 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2015 | 1996 | 0.020 |
Why?
| | Adolescent | 2 | 2019 | 21513 | 0.020 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1081 | 0.020 |
Why?
| | Infant | 1 | 2019 | 9465 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7635 | 0.010 |
Why?
| | DNA Methylation | 1 | 2010 | 643 | 0.010 |
Why?
| | Peptides | 1 | 2010 | 985 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 11074 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1091 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2129 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2189 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2010 | 3556 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 2836 | 0.010 |
Why?
| | Child | 1 | 2019 | 21935 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2010 | 2253 | 0.010 |
Why?
| | Lung | 1 | 2010 | 4060 | 0.010 |
Why?
|
|
Khan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|